Research on CAR-T treatments for solid tumors continues to expand as Gnubiotics Sciences, a Swiss biotech company pioneering immunomodulatory glycopeptides, announced an agreement with Penn to explore combining CAR-T therapy with Gnubiotics’ GLAAD technology to target solid tumors.
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, assistant professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine. Read the full article on the Gnubiotics website here.